Literature DB >> 7982964

cDNA cloning of the human tumor motility-stimulating protein, autotaxin, reveals a homology with phosphodiesterases.

J Murata1, H Y Lee, T Clair, H C Krutzsch, A A Arestad, M E Sobel, L A Liotta, M L Stracke.   

Abstract

A human cDNA clone encoding autotaxin, a tumor cell motility-stimulating protein, reveals that this protein is an ecto/exo-enzyme with significant homology to the plasma cell membrane differentiation antigen PC-1. ATX is a 125-kDa glycoprotein, previously isolated from a human melanoma cell line (A2058), which elicits chemotactic and chemokinetic responses at picomolar to nanomolar concentrations. Affinity-purified antipeptide antibodies to the ATX peptide, ATX-102, were employed to screen an A2058 cDNA expression library made in lambda gt11. The partial cDNA sequence which was obtained was then extended by utilizing reverse transcriptase on total cellular RNA followed by polymerase chain reaction amplification. The isolated cDNA clone contained 3251 base pairs, and the mRNA message size was approximately 3.3 kilobases. The deduced amino acid sequence of autotaxin matched 30 previously sequenced peptides and comprised a protein of 915 amino acids. Data base analysis of the ATX sequence revealed a 45% amino acid identity (including 30 out of 33 cysteines) with PC-1, a pyrophosphatase/type I phosphodiesterase expressed on the surface of activated B cells and plasma cells. ATX, like PC-1, was found to hydrolyze the type I phosphodiesterase substrate p-nitrophenyl thymidine-5'-monophosphate. Autotaxin now defines a novel motility-regulating function for this class of ecto/exo-enzymes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7982964

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  56 in total

1.  Characterization of a di-leucine-based signal in the cytoplasmic tail of the nucleotide-pyrophosphatase NPP1 that mediates basolateral targeting but not endocytosis.

Authors:  V Bello; J W Goding; V Greengrass; A Sali; V Dubljevic; C Lenoir; G Trugnan; M Maurice
Journal:  Mol Biol Cell       Date:  2001-10       Impact factor: 4.138

2.  Lysophosphatidic acid effects on atherosclerosis and thrombosis.

Authors:  Mei-Zhen Cui
Journal:  Clin Lipidol       Date:  2011-08

3.  Functional characterization of the non-catalytic ectodomains of the nucleotide pyrophosphatase/phosphodiesterase NPP1.

Authors:  Rik Gijsbers; Hugo Ceulemans; Mathieu Bollen
Journal:  Biochem J       Date:  2003-04-15       Impact factor: 3.857

4.  Ligand-based autotaxin pharmacophore models reflect structure-based docking results.

Authors:  Catrina D Mize; Ashley M Abbott; Samantha B Gacasan; Abby L Parrill; Daniel L Baker
Journal:  J Mol Graph Model       Date:  2011-09-18       Impact factor: 2.518

5.  ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.

Authors:  Yuzo Iwaki; Akira Ohhata; Shingo Nakatani; Katsuya Hisaichi; Yasuyuki Okabe; Atsushi Hiramatsu; Toshihide Watanabe; Shingo Yamamoto; Taihei Nishiyama; Juta Kobayashi; Yasuo Hirooka; Hideki Moriguchi; Tatsuo Maeda; Makoto Katoh; Yuka Komichi; Hiroto Ota; Naoya Matsumura; Masahiro Okada; Tetsuya Sugiyama; Hiroshi Saga; Akira Imagawa
Journal:  ACS Med Chem Lett       Date:  2020-05-14       Impact factor: 4.345

Review 6.  Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance.

Authors:  Mu-En Lin; Deron R Herr; Jerold Chun
Journal:  Prostaglandins Other Lipid Mediat       Date:  2009-03-04       Impact factor: 3.072

Review 7.  International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy.

Authors:  Maria P Abbracchio; Geoffrey Burnstock; Jean-Marie Boeynaems; Eric A Barnard; José L Boyer; Charles Kennedy; Gillian E Knight; Marta Fumagalli; Christian Gachet; Kenneth A Jacobson; Gary A Weisman
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

8.  Autotaxin inhibitors: a perspective on initial medicinal chemistry efforts.

Authors:  Abby L Parrill; Daniel L Baker
Journal:  Expert Opin Ther Pat       Date:  2010-11-04       Impact factor: 6.674

9.  Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity.

Authors:  Gilles Ferry; Edwige Tellier; Anne Try; Sandra Grés; Isabelle Naime; Marie Françoise Simon; Marianne Rodriguez; Jérémie Boucher; Ivan Tack; Stéphane Gesta; Pascale Chomarat; Marc Dieu; Martine Raes; Jean Pierre Galizzi; Philippe Valet; Jean A Boutin; Jean Sébastien Saulnier-Blache
Journal:  J Biol Chem       Date:  2003-03-17       Impact factor: 5.157

10.  Involvement of the lysophosphatidic acid-generating enzyme autotaxin in lymphocyte-endothelial cell interactions.

Authors:  Tae Nakasaki; Toshiyuki Tanaka; Shinichi Okudaira; Michi Hirosawa; Eiji Umemoto; Kazuhiro Otani; Soojung Jin; Zhongbin Bai; Haruko Hayasaka; Yoshinori Fukui; Katsuyuki Aozasa; Naoya Fujita; Takashi Tsuruo; Keiichi Ozono; Junken Aoki; Masayuki Miyasaka
Journal:  Am J Pathol       Date:  2008-09-25       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.